164 related articles for article (PubMed ID: 24748192)
21. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
22. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
23. [Values of Detecting the Levels of β2-MG, TNF-α, CRP, IL-6 in the Patients with Multiple Myeloma].
Duan LJ; Li C; Yang RY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1362-5. PubMed ID: 26524038
[TBL] [Abstract][Full Text] [Related]
24. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
26. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer.
Li C; Wang X; Casal I; Wang J; Li P; Zhang W; Xu E; Lai M; Zhang H
J Cell Mol Med; 2016 Aug; 20(8):1420-6. PubMed ID: 26990020
[TBL] [Abstract][Full Text] [Related]
27. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
29. Expression of Peripheral Blood miRNA-720 and miRNA-1246 Can Be Used as a Predictor for Outcome in Multiple Myeloma Patients.
Ren Y; Li X; Wang W; He W; Wang J; Wang Y
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):415-423. PubMed ID: 28601493
[TBL] [Abstract][Full Text] [Related]
30. Serum oncostatin M in multiple myeloma: association with prognostic factors.
Koskela K; Pelliniemi TT; Remes K; Rajamäki A; Pulkki K
Br J Haematol; 1997 Jan; 96(1):158-60. PubMed ID: 9012701
[TBL] [Abstract][Full Text] [Related]
31. Plasma GDF15 level is elevated in psychosis and inversely correlated with severity.
Kumar P; Millischer V; Villaescusa JC; Nilsson IAK; Östenson CG; Schalling M; Ösby U; Lavebratt C
Sci Rep; 2017 Aug; 7(1):7906. PubMed ID: 28801589
[TBL] [Abstract][Full Text] [Related]
32. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of bone sialoprotein, osteopontin, and β2-microglobulin in stage I of multiple myeloma.
Maaroufi A; Khadem-Ansari MH; Khalkhali HR; Rasmi Y
J Cancer Res Ther; 2020; 16(1):98-101. PubMed ID: 32362616
[TBL] [Abstract][Full Text] [Related]
35. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
36. [Prognositic factors in multiple myeloma].
Nagura E
Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282
[TBL] [Abstract][Full Text] [Related]
37. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
38. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes.
Ong F; Kaiser U; Seelen PJ; Hermans J; Wijermans PW; de Kieviet W; Jaques G; Kluin-Nelemans JC
Blood; 1996 Jan; 87(2):712-6. PubMed ID: 8555495
[TBL] [Abstract][Full Text] [Related]
39. [Expression and Clinical Significance of Heat Shock Protein 90 in Multiple Myeloma Patients].
Wu SQ; Chen HJ; Zhan R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):525-529. PubMed ID: 33812425
[TBL] [Abstract][Full Text] [Related]
40. Factors useful for predicting survival of myeloma patients in everyday practice. A 10-year study of 148 patients older than 55 years.
Chombart B; Lemoussu LG; Eschard JP; Ackah-Miezan S; Novella JL; Brochot P; Pignon B; Etienne JC
Joint Bone Spine; 2005 Dec; 72(6):544-9. PubMed ID: 16226477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
